Phenotypically adapted mycobacterium tuberculosis populations from sputum are tolerant to first-line drugs

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2476-2483

  Turapov, Obolbek ^a   O'Connor, Benjamin D ^a   Sarybaeva, Asel A ^a   Williams, Caroline ^a   Patel, Hemu ^b   Kadyrov, Abdullaat S ^c   Sarybaev, Akpay S ^d   Woltmann, Gerrit ^e   Barer, Michael R ^a,b   Mukamolova, Galina V ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c National Center of Phthisiology   (Kyrgyzstan)

^d Kyrgyz Indian Mountain Biomedical Research Center   (Kyrgyzstan)

^e GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CRYOPRESERVATION; DRUG EFFICACY; DRUG TOLERABILITY; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPUTUM CULTURE; ADAPTATION; ANTIBIOTIC RESISTANCE; BIOASSAY; CLASSIFICATION; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING; PHYSIOLOGY; SPUTUM;

ADAPTATION, PHYSIOLOGICAL; ANTITUBERCULAR AGENTS; BIOLOGICAL ASSAY; CRYOPRESERVATION; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; SPUTUM; STREPTOMYCIN; TUBERCULOSIS, PULMONARY;

EID: 84963745503     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01380-15     Document Type: Article

References (34)

1. Zumla A, George A, Sharma V, Herbert RH, Baroness Masham of Ilton, Oxley A, Oliver M. 2015. The WHO 2014 global tuberculosis report-further to go. Lancet Glob Health 3:e10-e12. http://dx.doi.org/10.1016/S2214-109X (14) 70361-4.
2. Mitchison D, Davies G. 2012. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16:724-732. http://dx.doi.org/10.5588/ijtld.12.0083.
3. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A. 2009. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9:162-172. http://dx.doi.org/10.1016/S1473-3099 (09) 70042-8.
4. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, Hinds J, Rajakumar K, Adegbola RA, Besra GS, Butcher PD, Barer MR. 2008. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5:e75. http://dx.doi.org/10.1371/journal.pmed.0050075.
5. Dhillon J, Fourie PB, Mitchison DA. 2014. Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media. J Antimicrob Chemother 69:437-440. http://dx.doi.org/10.1093/jac/dkt357.
6. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. 2010. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 181:174-180. http://dx.doi.org/10.1164/rccm.200905-0661OC.
7. Turapov O, Glenn S, Kana B, Makarov V, Andrew PW, Mukamolova GV. 2014. The in vivo environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria. Am J Respir Crit Care Med 190:1455-1457. http://dx.doi.org/10.1164/rccm.201407-1289LE.
8. Manina G, Dhar N, McKinney JD. 2015. Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe 17:32-46. http://dx.doi.org/10.1016/j.chom.2014.11.016.
9. Coates AR, Hu Y, Jindani A, Mitchison DA. 2013. Contradictory results with high-dosage rifamycinin mice and humans. Antimicrob Agents Chemother 57:1103. http://dx.doi.org/10.1128/AAC.01705-12.
10. Kim TH, Kubica GP. 1972. Long-term preservation and storage of mycobacteria. Appl Microbiol 24:311-317.
11. Giampaglia CM, de Brito AC, Martins MC, Ueki SY, Latrilha FO, de Oliveira RS, Yamauchi JU, da Silva Telles MA. 2009. Maintenance of Mycobacterium tuberculosis on glass beads. Ann Clin Lab Sci 39:51-54.
12. Shu Z, Weigel KM, Soelberg SD, Lakey A, Cangelosi GA, Lee KH, Chung JH, Gao D. 2012. Cryopreservation of Mycobacterium tuberculosis complex cells. J Clin Microbiol 50:3575-3580. http://dx.doi.org/10.1128/JCM.00896-12.
13. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. 2011. Rate of recovery of Mycobacterium tuberculosis from frozen acid-fast-bacillus smear-positive sputum samples subjected to long-term storage in northwest Ethiopia. J Clin Microbiol 49:2557-2561. http://dx.doi.org/10.1128/JCM.00059-11.
14. Selvakumar N, Sudhamathi S, Duraipandian M, Frieden TR, Narayanan PR. 2004. Reduced detection by Ziehl-Neelsen method of acid-fast bacilli in sputum samples preserved in cetylpyridinium chloride solution. Int J Tuberc Lung Dis 8:248-252.
15. Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. 2010. MIRU-VNTRplus: a Web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res 38:W326-W331. http://dx.doi.org/10.1093/nar/gkq351.
16. Mukamolova GV, Turapov OA, Young DI, Kaprelyants AS, Kell DB, Young M. 2002. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol Microbiol 46:623-635. http://dx.doi.org/10.1046/j.1365-2958.2002.03184.x.
17. Turapov O, Waddell SJ, Burke B, Glenn S, Sarybaeva AS, Tudo G, Labesse G, Young DI, Young M, Andrew PW, Butcher PD, Gohen-Gonsaud M, Mukamolova GV. 2014. Antimicrobial treatment improves mycobacterial survival in non-permissive growth conditions. Antimicrobial Agents Chemother 58:2798-2806. http://dx.doi.org/10.1128/AAC.02774-13.
18. Brown-Elliott BA, Cohen S, Wallace RJ, Jr. 2007. Susceptibility testing of mycobacteria, p 243-254. In Schwalbe R, Steele-Moore L, Goodwin AC, Antimicrobial susceptibility testing protocols. CRC Press, Boca Raton, FL.
19. Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH. 2015. The relationship between Mycobacterium tuberculosis MGIT time to positivity and CFU in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. J Antimicrob Chemother 70:448-455. http://dx.doi.org/10.1093/jac/dku415.
20. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139-163. http://dx.doi.org/10.1146/annurev. micro.55.1.139.
21. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA, for the RIFAQUIN Trial Team. 2014. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:1599-1608. http://dx.doi.org/10.1056/NEJMoa1314210.
22. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ, REMoxTB Consortium. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:1577-1587. http://dx.doi.org/10.1056/NEJM oa1407426.
23. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds againstMycobacterium tuberculosis. Tuberculosis (Edinb) 92:453-488. http://dx.doi.org/10.1016/j.tube.2012.07.003.
24. Kaprelyants AS, Mukamolova GV, Ruggiero A, Makarov VA, Demina GR, Shleeva MO, Potapov VD, Shramko PA. 2012. Resuscitationpromoting factors (Rpf): in search of inhibitors. Protein Pept Lett 19:1026-1034. http://dx.doi.org/10.2174/092986612802762723.
25. O'Connor BD, Woltmann G, Patel H, Turapov O, Haldar P, Mukamolova GV. 2015. Can resuscitation-promoting factors be used to improve culture rates of extrapulmonary tuberculosis? Int J Tuberc Lung Dis 619:1556-1557. http://dx.doi.org/10.5588/ijtld.15.0682.
26. Friedrich SO Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M, Pan African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA). 2013. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 1:462-470. http://dx.doi.org/10.1016/S2213-2600 (13) 70119-X.
27. Kolwijck E, Friedrich SO, Karinja MN, van Ingen J, Warren RM, Diacon AH. 2014. Early stationary phase culture supernatant accelerates growth of sputum cultures collected after initiation of anti-tuberculosis treatment. Clin Microbiol Infect 20:O418-O420. http://dx.doi.org/10.1111/1469-0691.12441.
28. Bonalsky JR, Jaconia D, Konopka EA, Adair FW. 1975. Analysis of rifampin disk diffusion and stability in 7H10 agar. Antimicrob Agents Chemother 8:187-193. http://dx.doi.org/10.1128/AAC.8.2.187.
29. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
30. Manina G, McKinney JD. 2013. A single-cell perspective on non-growing but metabolically active (NGMA) bacteria. Curr Top Microbiol Immunol 374:135-161. http://dx.doi.org/10.1007/82-2013-333.
31. Hu Y, Liu A, Ortega-Muro F, Alameda-Martin L, Mitchison D, Coates A. 2015. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol 6:641. http://dx.doi.org/10.3389/fmicb.2015.00641.
32. Sloan DJ, Mwandumba HC, Garton NJ, Khoo SH, Butterworth AE, Allain TJ, Heyderman RS, Corbett EL, Barer MR, Davies GR. 2015. Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatmentofpulmonary tuberculosis. Clin Infect Dis 61:1-8. http://dx.doi.org/10.1093/cid/civ195.
33. Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N, Pan African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics. 2014. The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. J Clin Microbiol 52:3064-3067. http://dx.doi.org/10.1128/JCM.01128-14.
34. Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. 2015. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. J Infect Dis 212:990-998. http://dx.doi.org/10.1093/infdis/jiv149.